Intramolecular Oxycyanation of Alkenes by Cooperative Pd/BPh<sub>3</sub> Catalysis
作者:Dennis C. Koester、Masato Kobayashi、Daniel B. Werz、Yoshiaki Nakao
DOI:10.1021/ja301375c
日期:2012.4.18
intramolecular oxycyanation of alkenes through the cleavage of O-CN bonds and the subsequent insertion of double bonds. The use of 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos) as a ligand for palladium is essential for allowing the transformation to proceed with high chemo- and regioselectivity. Variously substituted dihydrobenzofurans with both a tetra-substituted carbon and cyano functionality
Palladium-catalyzed heteroallylation of unactivated alkenes – synthesis of citalopram
作者:Joanne F. M. Hewitt、Lewis Williams、Pooja Aggarwal、Craig D. Smith、David J. France
DOI:10.1039/c3sc51222c
日期:——
A palladium-catalyzed difunctionalization of unactivated alkenes with tethered nucleophiles is reported. The versatile reaction occurs with simple allylic halides and can be carried out under air. The methodology provides rapid access to a wide array of desirable heterocyclic targets, as illustrated by a concise synthesis of the widely prescribed antidepressantcitalopram.
The present invention provides compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as modulators of liver X receptors (LXR), compositions comprising any of such novel compounds, methods of using these compounds or compositions as medicaments for prevention or treatment of diseases or disorders related to liver X receptor (LXR), as well as methods of preparing these LXR modulators and using them in the manufacture of medicaments.
chemistry is reported. Both phenol and aromatic or aliphatic acid derivatives could be used under operator-friendly conditions (room temperature, technical solvents, under air). The discovery of the superiority of benziodoxolone-derived hypervalent iodine reagent 3d as an alkyne transfer reagent further expands the rapidly increasing utility of hypervalent iodine reagents in catalysis and is expected
Pyrimidine compounds and methods of making and using same
申请人:Cystic Fibrosis Foundation Therapeutics, Inc.
公开号:US08334292B1
公开(公告)日:2012-12-18
Disclosed herein are pyrimidinyl compounds that are contemplated to be modulators of cystic fibrosis transmembrane regulators (CFTR), and methods of making and using same. Also provided are pharmaceutical compositions and methods of treating disorders associated with cystic fibrosis transmembrane regulators, such as airway inflammation, cystic fibrosis, and the like.